Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO EBITDA Margin
EBITDA as a percentage of revenue.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -2088.6%
EBITDA Margin was -2088.6% in Q1 FY2026, down 1645.0 pp from a year earlier. On a trailing-twelve-month basis it was -339.9%, down 229.0 pp year over year. Over 3 fiscal years it narrowed by 131.5 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -91.0% for the fiscal year ending Dec 2026, up from -293.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2088.6%-1835.0 pp QoQ
- Last fiscal yearDec 2025
- -293.0%-138.9 pp YoY
- LTMMar 2026
- -339.9%-229.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -293.0%
- Year-over-year change
- -138.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -293.0% | -138.9pp |
| FY2024 | 2024-12-31 | -154.1% | -99.2pp |
| FY2023 | 2023-12-31 | -54.9% | +106.6pp |
| FY2022 | 2022-12-31 | -161.5% | -16.6pp |
| FY2021 | 2021-12-31 | -144.9% | — |
EBITDA Margin vs competitors
How SGMO compares with its peers on the latest reported figures
- SGMO's LTM Mar 2026 EBITDA Margin of -339.9% is the 5th highest of the 10 companies compared; the peer median is -1053.3%.
- Its year-over-year change of -229.0 pp is the 6th highest of 9, against a peer median of +2.9 pp.
- Over three fiscal years its change of -131.5 pp compares with a peer median of -225.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -28.2% | +91.2 pp | -29.1 pp | |
| LTM Mar 2026 | -117.0% | +50.4 pp | -225.4 pp | |
| LTM Mar 2026 | -135.5% | +244.4 pp | — | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -339.9% | -229.0 pp | -131.5 pp | |
| LTM Mar 2026 | -1053.3% | +3016.0 pp | — | |
| FY2025 | -1566.1% | -1194.4 pp | -1544.8 pp | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2329.5% | -862.2 pp | +207.6 pp |
| LTM Mar 2026 | -3439.7% | — | -2679.5 pp | |
| LTM Mar 2026 | -8872.8% | -9159.7 pp | -2521.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding SGMO) | -1053.3% | +2.9 pp | -225.4 pp | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| Weighted Avg Shares | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
| Weighted Avg Shares (Diluted) | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.